AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03055442 — intervention group
Intervention type: OTHER
Intervention: Dosage of D-chiro-inositol
Description: Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
Study NCT01200264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apremilast
Description: apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
Study NCT04572126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Intervention
Description: The mindfulness intervention includes strategies to cope with substance cravings based on previously published mindfulness techniques. Examples of strategies presented include paying close attention to sensations, acceptance of cravings, and self-kindness.
Study NCT04572126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: The control intervention instructs participants to utilize their own, previously used strategies to cope with substance cravings.
Study NCT02503020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm infants formula A
Description: Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
Study NCT02503020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm infants formula B
Description: Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age.
Study NCT02099695 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
Study NCT02099695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The quantity of tablets will increase due to the absence/ lack of therapeutic response.
Study NCT03053219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
Study NCT00833742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Short-term Dynamic Psychotherapy
Description: A brief psychotherapy format
Study NCT01732484 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraocular lens implantation
Study NCT02613013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium:yttrium-aluminum- garnet laser
Description: a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
Study NCT02613013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neodymium:yttrium-aluminum- garnet laser
Description: a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
Study NCT02613013 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser
Description: a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
Study NCT02613013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Study NCT02613013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Study NCT02613013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPIP plus LPI
Description: LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
Study NCT02613013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Study NCT02613013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proparacaine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Study NCT02613013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LPI
Description: LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
Study NCT01513564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative epidural morphine
Description: The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
Study NCT01513564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Description: Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
Study NCT00697684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Study NCT00697684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
Study NCT00697684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
Study NCT04943419 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Myeloid-Derived Suppressor Cells
Description: Establishing of levels of all MDSC, PMNMDSC, MMDSC, EMDSC, M/PMN MDSC ratio on the day before operation.
Study NCT02247817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid CRT-D/P implantation
Study NCT00697684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
Study NCT04370951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block - Ultrasound guided
Description: 20mls 0.25% Levobupivicaine ultrasound guided bilaterally
Study NCT00774696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin 500mg tablets
Study NCT00774696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin 500mg tablets
Study NCT03880799 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Session
Description: one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
Study NCT03561441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored aggressive hydration
Description: 1. Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked.
Study NCT03561441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tailored standard hydration
Description: 1. Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~2. At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~3. At 8 hours, if pain (\<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked.
Study NCT02813057 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stoppa inguinal hernia repair
Description: Stoppa inguinal hernia repair
Study NCT02813057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total extraperitoneal inguinal hernia repair
Description: Total extraperitoneal inguinal hernia repair
Study NCT01681602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
Study NCT00856973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
Study NCT00856973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
Study NCT00856973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day for 12 weeks
Study NCT02969941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study NCT02969941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study NCT01019863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
Study NCT00302081 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 1.5 mcg/kg QW SC for 24 weeks
Study NCT00302081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 1.0 mcg/kg QW SC for 24 weeks
Study NCT01559064 — intervention group
Intervention type: DEVICE
Intervention: Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)
Description: All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
Study NCT03801356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Selective Nerve Root Block
Description: Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
Study NCT01703611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MNT according to AND EBNPG for Type 2 DM
Description: Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
Study NCT00302081 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (SCH 54031)
Description: 1.5 mcg/kg QW SC for 16 weeks
Study NCT00302081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (SCH 18908)
Description: 800-1200 mg daily for 24 weeks
Study NCT00302081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin (SCH 18908)
Description: 800-1200 mg daily for 24 weeks
Study NCT00302081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (SCH 18908)
Description: 800-1200 mg daily for 16 weeks
Study NCT03733210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab-IRDye800
Description: 30 mg administered intravenously (IV)
Study NCT01703611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Nutrition Care
Description: Usual nutrition care in India
Study NCT03733210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89-Zirconium (Zr-89) Panitumumab
Description: 0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
Study NCT03733210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinpoint IR IR9000 fluorescence imaging system (FIS)
Description: Handheld fluorescence-imaging endoscope manufactured by Novadaq
Study NCT03733210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY-PHI IR9000 fluorescence imaging system (FIS)
Description: Handheld fluorescence-imaging endoscope manufactured by Novadaq
Study NCT02308761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
Study NCT03368066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
Study NCT03733210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Explorer Air camera
Description: Fluorescence camera manufactured by SurgVision
Study NCT01046383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMN1207
Description: 20 grams of IMN1207 per day for 40 weeks.
Study NCT01046383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Casein
Description: 20 grams of Casein per day for 40 weeks
Study NCT01714297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin 5000 IU s.c.
Description: All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
Study NCT01714297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dalteparin 5000 IU s.c.
Description: All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
Study NCT04875949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immunoabsorption/plasmapheresis procedure
Study NCT00553631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: velaglucerase alfa
Description: IV infusion, 60 U/kg every other week for 9 months
Study NCT00862121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentasa
Description: 6 g/day orally, 2 g in the morning and 4 g in the evening
Study NCT00862121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 g/day orally, 2 g in the morning and 4 g in the evening
Study NCT01892397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune (NovoTTF-100A)
Study NCT04209257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation.
Description: Functional electrical stimulation - electrical stimulation applied to a muscle during an activity (i.e. ankle dorsiflexors during swing phase of gait). It assists / elicits muscle activation in order to achieve a task.
Study NCT00553631 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: imiglucerase
Description: IV infusion, 60 U/kg every other week for 9 months
Study NCT00950651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl Contramid® Once A Day
Description: The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Study NCT00950651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol HCl Twice a day
Description: The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Study NCT01044030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol syrup
Description: 7.5 mL (5 grams) by mouth three times daily
Study NCT02521688 — intervention group
Intervention type: PROCEDURE
Intervention: incisional biopsy from placenta and GCF sample
Description: A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
Study NCT01044030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.5 mL by mouth three times daily
Study NCT02046018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM delivered by VHT
Description: VHT's deliver ICCM to children under five in their communities
Study NCT02046018 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM delivered by VHT with Cell Phone
Description: ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
Study NCT03787732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid Bolus
Description: 500 milliliters of an intravenous crystalloid solution of the operator's choosing
Study NCT03787732 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Fluid Bolus
Description: No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation